Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. has reported developments tied to its history as a clinical-stage biopharmaceutical company developing small molecule therapeutics for immune-mediated diseases. Company updates have centered on zetomipzomib, a selective immunoproteasome inhibitor evaluated in autoimmune hepatitis and other chronic immune-mediated diseases, including clinical data presentations and FDA regulatory correspondence.
Other recurring developments include operating and financial results, cost-containment measures, strategic review actions, the completed sale of Sec61-based discovery and development assets including KZR-261 to Enodia Therapeutics, and corporate transaction matters following Aurinia-related acquisition activity and Nasdaq delisting procedures.
Kezar Life Sciences (Nasdaq: KZR) has voluntarily ceased enrollment and dosing in its Phase 2b PALIZADE trial of zetomipzomib for active lupus nephritis. This decision follows the recommendation of the Independent Data Monitoring Committee after reviewing emerging safety data, including four Grade 5 (fatal) serious adverse events in patients from the Philippines and Argentina. Three fatalities showed a common pattern of symptoms and proximity to dosing. Kezar remains blinded to which patients were on zetomipzomib or placebo.
The ongoing Phase 2a PORTOLA trial for autoimmune hepatitis continues, with no Grade 4 or 5 SAEs observed. Kezar is evaluating the data to determine next steps and potential risk mitigation strategies. The company has notified study investigators and is informing regulatory authorities. No formal FDA clinical hold has been issued yet.
Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech firm focusing on novel small molecule therapeutics for immune-mediated diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, at 12:00 pm ET in New York, NY.
Chris Kirk, Co-founder and CEO of Kezar, will deliver a corporate overview during the presentation. Investors and interested parties can access a live webcast of the presentation through the "Events & Presentations" section on Kezar's official website. An archived version of the webcast will remain available on the site for 90 days following the event, providing extended access to the company's latest updates and strategic outlook.
Kezar Life Sciences (Nasdaq: KZR) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Completed enrollment in PORTOLA Phase 2a trial of zetomipzomib for autoimmune hepatitis; topline data expected in H1 2025.
2. PALIZADE Phase 2b trial of zetomipzomib for lupus nephritis ongoing; topline data expected mid-2026.
3. Stopped enrollment in KZR-261 Phase 1 study for solid tumors; focusing resources on zetomipzomib programs.
4. Cash, cash equivalents, and marketable securities totaled $164.2 million as of June 30, 2024.
5. Q2 2024 net loss of $21.5 million ($0.30 per share) compared to $24.3 million ($0.34 per share) in Q2 2023.
6. R&D expenses decreased to $16.3 million from $21.0 million in Q2 2023.
Kezar Life Sciences (Nasdaq: KZR) has announced the granting of a nonqualified stock option to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4). The option allows the purchase of 72,000 shares at $0.55 per share, matching the closing price on July 8, 2024. The award aims to attract the individual to join Kezar. The stock options will vest over four years: 25% on the first anniversary of the employee’s start date, and 1/48th monthly thereafter, conditional on continued employment. The grant is governed by Kezar’s 2022 Inducement Plan and specific stock option agreement.
Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech firm, announced a nonqualified stock option grant to purchase 80,000 shares at $0.71 per share.
The stock option, granted to a new employee on June 3, 2024, is in line with Nasdaq Listing Rule 5635(c)(4). The grant is part of Kezar's strategy to attract top talent.
The options will vest over four years: 25% after the first year, with the remainder vesting monthly. This grant is material to the individual’s employment agreement and is part of Kezar's 2022 Inducement Plan.
Kezar Life Sciences, a clinical-stage biotechnology company listed on Nasdaq (KZR), announced that its CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 12:30 pm ET in New York. The company focuses on developing novel small molecule therapeutics for immune-mediated diseases and cancer. The event will be webcasted live and available on Kezar's website for 90 days post-event.
Kezar Life Sciences, Inc. reported its first quarter 2024 financial results and business update, including progress in clinical trials for zetomipzomib in lupus nephritis and autoimmune hepatitis, and dose expansion for KZR-261 in melanoma. Cash, cash equivalents, and marketable securities totaled $179.8 million. R&D expenses decreased to $17.2 million, while G&A expenses increased to $6.5 million. Net loss was $21.7 million for the quarter.
Kezar Life Sciences, Inc. granted two employees nonqualified stock options to purchase 164,000 shares of common stock at $0.84 per share under NASDAQ Listing Rule 5635(c)(4). The options will vest over four years, with 25% on the first anniversary and 1/48th monthly thereafter, contingent on continued employment.
Summary not available.
Summary not available.